|
|
 Previous Article | Table of Contents | Next Article 
The use of the dilute Russell viper venom time for the diagnosis of lupus
anticoagulants
P Thiagarajan, V Pengo and SS Shapiro
We describe here a test for lupus anticoagulants based on a modified
Russell viper venom time (RVVT), using limiting amounts of phospholipid and
venom. We have studied 29 patients with a prolonged dilute RVVT. Five of
the 29 had a normal activated partial thromboplastin time and three of 14
tested by the tissue thromboplastin inhibition test were normal. In 17 of
19 patients tested, the dilute RVVT was completely normal when
ionophore-treated platelets were substituted for phospholipid; the
remaining two patients, both with very long phospholipid-dependent dilute
RVVT's, were nearly completely normalized. The dilute RVVT is not prolonged
in the presence of antibodies to factors VIII, IX, or XI. Thus, the dilute
RVVT appears to be a simple, reproducible, sensitive, and relatively
specific method for the detection of lupus anticoagulants.
Volume 68,
Issue 4,
pp. 869-874,
10/01/1986
Copyright © 1986 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
C. Kearon, J. A. Julian, M. J. Kovacs, D. R. Anderson, P. Wells, B. MacKinnon, J. I. Weitz, M. A. Crowther, S. Dolan, A. G. Turpie, et al.
Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial
Blood,
December 1, 2008;
112(12):
4432 - 4436.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Ghosh, S. Shetty, S. Vora, and V. Salvi
Successful Pregnancy Outcome in Women With Bad Obstetric History and Recurrent Fetal Loss Due to Thrombophilia: Effect of Unfractionated Heparin and Low--Molecular Weight Heparin
Clinical and Applied Thrombosis/Hemostasis,
April 1, 2008;
14(2):
174 - 179.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Tripodi
Laboratory Testing for Lupus Anticoagulants: A Review of Issues Affecting Results
Clin. Chem.,
September 1, 2007;
53(9):
1629 - 1635.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Abo and V. A. DeBari
Laboratory Evaluation of the Antiphospholipid Syndrome
Ann. Clin. Lab. Sci.,
January 1, 2007;
37(1):
3 - 14.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Proven, R. P. Bartlett, K. G. Moder, A. Chang-Miller, L. K. Cardel, J. A. Heit, H. A. Homburger, T. M. Petterson, T. J. H. Christianson, and W. L. Nichols
Clinical Importance of Positive Test Results for Lupus Anticoagulant and Anticardiolipin Antibodies
Mayo Clin. Proc.,
April 1, 2004;
79(4):
467 - 475.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Cugno, M. Cabibbe, M. Galli, P. L. Meroni, S. Caccia, R. Russo, B. Bottasso, and P. M. Mannucci
Antibodies to tissue-type plasminogen activator (tPA) in patients with antiphospholipid syndrome: evidence of interaction between the antibodies and the catalytic domain of tPA in 2 patients
Blood,
March 15, 2004;
103(6):
2121 - 2126.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Gerbutavicius, O. Iqbal, H. L. Messmore, W. H. Wehrmacher, D. A. Hoppensteadt, R. Gerbutaviciene, R. Griniute, and J. Fareed
Differential Effects of DX-9065a, Argatroban, and Synthetic Pentasaccharide on Tissue Thromboplastin Inhibition Test and Dilute Russell's Viper Venom Test
Clinical and Applied Thrombosis/Hemostasis,
October 1, 2003;
9(4):
317 - 323.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Tripodi, A. Biasiolo, V. Chantarangkul, and V. Pengo
Lupus Anticoagulant (LA) Testing: Performance of Clinical Laboratories Assessed by a National Survey Using Lyophilized Affinity-purified Immunoglobulin with LA Activity
Clin. Chem.,
October 1, 2003;
49(10):
1608 - 1614.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F-J Munoz-Rodriguez, J-C Reverter, J Font, D Tassies, G Espinosa, R Cervera, F Carmona, J Balasch, M Ingelmo, and A Ordinas
Clinical significance of acquired activated protein C resistance in patients with systemic lupus erythematosus
Lupus,
November 1, 2002;
11(11):
730 - 735.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. Gerbutavicius, J. Fareed, H. L. Messmore Jr, O. Iqbal, D. A. Hoppensteadt, W. H. Wehrmacher, M. Demir, P. Piccolo, S. Ahmad, Q. Ma, et al.
Reference Intervals of the Dilute Tissue Thromboplastin Inhibition and Dilute Russell's Viper Venom Tests Revisited
Clinical and Applied Thrombosis/Hemostasis,
April 1, 2002;
8(2):
115 - 124.
[Abstract]
[PDF]
|
|
|
|
|
|
|
E. Lindhoff-Last, M. Humpich, J. Schmitt, S. Rodiger, E. Seifried, and R. Bauersachs
MIXCON-LA: A Precise, Sensitive and Specific aPTT-Based Assay for Detection of Lupus Anticoagulant
Clinical and Applied Thrombosis/Hemostasis,
April 1, 2002;
8(2):
163 - 167.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. Gerbutavicius, J. Fareed, H. L. Messmore, O. Jqbal, W. H. Wehrmacher, D. A. Hoppensteadt, M. Demir, P. Piccolo, S. Ahmad, Q. Ma, et al.
Reference Ranges of the Dilute Tissue Thromboplastin Inhibition and Dilute Russell's Viper Venom Tests Revisited
Clinical and Applied Thrombosis/Hemostasis,
January 1, 2002;
8(1):
51 - 59.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. L. Bick
State-of-the-Art Review: Antiphospholipid Thrombosis Syndromes
Clinical and Applied Thrombosis/Hemostasis,
October 1, 2001;
7(4):
241 - 258.
[PDF]
|
|
|
|
|
|
|
S.-Q. Kuang, S. Hasham, M. D. Phillips, D. Wolf, Y. Wan, P. Thiagarajan, and D. M. Milewicz
Characterization of a novel autosomal dominant bleeding disorder in a large kindred from east Texas
Blood,
March 15, 2001;
97(6):
1549 - 1554.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Bick and R. G. Scott
Stasis Ulcers Refractory to Therapy--Accelerated Healing by Treatment With Clopidogrel {+/-} Dalteparin: A Preliminary Report
Clinical and Applied Thrombosis/Hemostasis,
January 1, 2001;
7(1):
21 - 24.
[Abstract]
[PDF]
|
|
|
|
|
|
|
B. G. Macik, J. H. Rand, and B. A. Konkle
Thrombophilia: What's a Practitioner to Do?
Hematology,
January 1, 2001;
2001(1):
322 - 338.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Brill-Edwards, J. S. Ginsberg, M. Gent, J. Hirsh, R. Burrows, C. Kearon, W. Geerts, M. Kovacs, J. I. Weitz, K. S. Robinson, et al.
Safety of Withholding Heparin in Pregnant Women with a History of Venous Thromboembolism
N. Engl. J. Med.,
November 16, 2000;
343(20):
1439 - 1444.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Bick
Recurrent Miscarriage Syndrome due to Blood Coagulation Protein/Platelet Defects: Prevalence, Treatment and Outcome Results
Clinical and Applied Thrombosis/Hemostasis,
July 1, 2000;
6(3):
115 - 125.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Sakakura, H. Wada, R. Watanabe, M. Mamamuro, Y. Okugawa, T. Nakasaki, T. Nakase, Y. Wakita, K. Minamikawa, Y. Mori, et al.
State-of-the-Art Review : Coagulation Tests and Anti-Phospholipid Antibodies in Patients Positive for Lupus Anticoagulant
Clinical and Applied Thrombosis/Hemostasis,
July 1, 2000;
6(3):
144 - 150.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. Ordi-Ros, J. Villarreal, F. Monegal, S. Sauleda, I. Esteban, and M. Vilardell
Anticardiolipin Antibodies in Patients with Chronic Hepatitis C Virus Infection: Characterization in Relation to Antiphospholipid Syndrome
Clin. Vaccine Immunol.,
March 1, 2000;
7(2):
241 - 244.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F.B. KARASSA, J.P.A. IOANNIDIS, G. TOULOUMI, K.A. BOKI, and H.M. MOUTSOPOULOS
Risk factors for central nervous system involvement in systemic lupus erythematosus
QJM,
March 1, 2000;
93(3):
169 - 174.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Rodeghiero and A. Tosetto
Activated Protein C Resistance and Factor V Leiden Mutation Are Independent Risk Factors for Venous Thromboembolism
Ann Intern Med,
April 20, 1999;
130(8):
643 - 650.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Kearon, M. Gent, J. Hirsh, J. Weitz, M. J. Kovacs, D. R. Anderson, A. G. Turpie, D. Green, J. S. Ginsberg, P. Wells, et al.
A Comparison of Three Months of Anticoagulation with Extended Anticoagulation for a First Episode of Idiopathic Venous Thromboembolism
N. Engl. J. Med.,
March 25, 1999;
340(12):
901 - 907.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Wakita, H. Wada, T. Nakase, T. Nakasaki, M. Shimura, K. Hiyoyama, Y. Mori, E. C. Gabazza, M. Nishikawa, K. Deguchi, et al.
Aberrations of the Tissue Factor Pathway in Patients Positive for Lupus Anticoagulant
Clinical and Applied Thrombosis/Hemostasis,
January 1, 1999;
5(1):
10 - 15.
[Abstract]
[PDF]
|
|
|
|
|
|
|
V. Toschi, A. Motta, C. Castelli, M. L. Paracchini, D. Zerbi, and A. Gibelli
High Prevalence of Antiphosphatidylinositol Antibodies in Young Patients With Cerebral Ischemia of Undetermined Cause
Stroke,
September 1, 1998;
29(9):
1759 - 1764.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D A Kandiah and S A Krilis
Anti-{beta}2-glycoprotein I and anti-prothrombin antibodies in patients with the 'antiphospholipid' syndrome: Immunological specificity and clotting profiles
Lupus,
June 1, 1998;
7(5):
323 - 332.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D G Wahl, F Guillemin, E de Maistre, C Perret-Guillaume, T Lecompte, and G Thibaut
Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis
Lupus,
January 1, 1998;
7(1):
15 - 22.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. R. Carhuapoma, P. Mitsias, and S. R. Levine
Cerebral Venous Thrombosis and Anticardiolipin Antibodies
Stroke,
December 1, 1997;
28(12):
2363 - 2369.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
R. L. Bick
The Antiphospholipid Thrombosis Syndromes: A Common Multidisciplinary Medical Problem
Clinical and Applied Thrombosis/Hemostasis,
October 1, 1997;
3(4):
270 - 283.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. Granger and R. Farquharson
Review : Obstetric outcome in antiphospholipid syndrome
Lupus,
January 1, 1997;
6(6):
509 - 513.
[Abstract]
[PDF]
|
|
|
|
|
|
|
F. Martini, A. Farsi, A. Gori, M. Boddi, S. Fedi, M. Domeneghetti, A. Passaleva, D. Prisco, and R. Abbate
Antiphospholipid antibodies (aPL) increase the potential monocyte procoagulant activity in patients with systemic lupus erythematosus
Lupus,
June 1, 1996;
5(3):
206 - 211.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. L. Bick, H. R. Laughlin, B. M. Cohen, A. J. Staub, J. Madden, and A. Toofanian
Fetal Wastage Syndrome due to Blood Protein/Platelet Defects: Results of Prevalence Studies and Treatment Outcome with Low-Dose Heparin and Low-Dose Aspirin
Clinical and Applied Thrombosis/Hemostasis,
September 1, 1995;
1(4):
286 - 292.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. Armitage, J. Ashcraft, A. Kim, and H. S. Kaplan
An Approach to Factor Assays in Patients with Strong Lupus Anticoagulants
Clinical and Applied Thrombosis/Hemostasis,
March 1, 1995;
1(2):
125 - 130.
[Abstract]
[PDF]
|
|
|
|
|
|
|
W. F. Baker JR
Outcome Analysis for Treatment in 100 Patients with Deep Vein Thrombosis
Clinical and Applied Thrombosis/Hemostasis,
January 1, 1995;
1(1):
39 - 48.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. A. Triplett
Assays for Detection of Antiphospholipid Antibodies
Lupus,
August 1, 1994;
3(4):
281 - 287.
[PDF]
|
|
|
|
|
|
|
T. Jouhikainen, S. Pohjola-Sintonen, and E. Stephansson
Lupus Anticoagulant and Cardiac Manifestations in Systemic Lupus Erythematosus
Lupus,
June 1, 1994;
3(3):
167 - 172.
[Abstract]
[PDF]
|
|
|
|
|
|
|
H. Julkunen, T. Jouhikainen, R. Kaaja, M. Leirisalo-Repo, E. Stephansson, T. Palosuop, K. Teramo, and C. Friman
Fetal Outcome in Lupus Pregnancy: A Retrospective Case-Control Study of 242 Pregnancies in 112 Patients
Lupus,
April 1, 1993;
2(2):
125 - 131.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. R. Levine and K. M. A. Welch
The Spectrum of Neurologic Disease Associated With Antiphospholipid Antibodies: Lupus Anticoagulants and Anticardiolipin Antibodies
Arch Neurol,
August 1, 1987;
44(8):
876 - 883.
[Abstract]
[PDF]
|
|
|
|
|
